Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Drug Name Mix-Ups To Be Addressed In Sen. Kennedy's Patient Safety Bill

Executive Summary

FDA would be required to adopt a program to minimize drug name confusion under patient safety legislation proposed by Sen. Kennedy (D-Mass.).

You may also be interested in...



Rx Safety Gets More Attention From CERTs With Addition Of Health IT Center

The Centers for Education and Research on Therapeutics program will be adding a new center focused on health information technology

Rx Safety Gets More Attention From CERTs With Addition Of Health IT Center

The Centers for Education and Research on Therapeutics program will be adding a new center focused on health information technology

Sen. Jeffords To Hold Three Patient Safety Hearings On IoM And GAO Reports

Senate Health Committee Chairman Jeffords (R-Vt.) will hold at least three hearings in the coming session to discuss medical errors and patient safety, with one specifically focused on adverse drug events.

Related Content

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel